105 related articles for article (PubMed ID: 23353843)
21. Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent.
Monostory K; Pascussi JM; Szabó P; Temesvári M; Köhalmy K; Acimovic J; Kocjan D; Kuzman D; Wilzewski B; Bernhardt R; Kóbori L; Rozman D
Drug Metab Dispos; 2009 Feb; 37(2):375-85. PubMed ID: 18971317
[TBL] [Abstract][Full Text] [Related]
22. Rosuvastatin preconditioning provides neuroprotection against spinal cord ischemia in rats through modulating nitric oxide synthase expressions.
Die J; Wang K; Fan L; Jiang Y; Shi Z
Brain Res; 2010 Jul; 1346():251-61. PubMed ID: 20513366
[TBL] [Abstract][Full Text] [Related]
23. Effects of bile duct ligation on hepatic expression of female-specific CYP2C12 in male and female rats.
Chen J; Robertson G; Field J; Liddle C; Farrell GC
Hepatology; 1998 Sep; 28(3):624-30. PubMed ID: 9731550
[TBL] [Abstract][Full Text] [Related]
24. Factors involved in rosuvastatin induction of insulin sensitization in rats fed a high fat diet.
de las Heras N; Valero-Muñoz M; Ballesteros S; Gómez-Hernández A; Martín-Fernández B; Blanco-Rivero J; Cachofeiro V; Benito M; Balfagón G; Lahera V
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1107-14. PubMed ID: 23434394
[TBL] [Abstract][Full Text] [Related]
25. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation.
Gallelli L; Ferraro M; Spagnuolo V; Rende P; Mauro GF; De Sarro G
Drug Metabol Drug Interact; 2009; 24(1):83-7. PubMed ID: 19354002
[TBL] [Abstract][Full Text] [Related]
26. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Li XL; Guan RJ; Li JJ
J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
[TBL] [Abstract][Full Text] [Related]
27. Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart.
Ozturk N; Yaras N; Ozmen A; Ozdemir S
J Bioenerg Biomembr; 2013 Aug; 45(4):343-52. PubMed ID: 23640692
[TBL] [Abstract][Full Text] [Related]
28. Effect of rosuvastatin on obesity-induced cardiac oxidative stress in Wistar rats--a preliminary study.
Ansari JA; Bhandari U; Pillai KK; Haque SE
Indian J Exp Biol; 2012 Mar; 50(3):216-22. PubMed ID: 22439437
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation of rat hepatic microsomal cytochromes P-450 in microvesicular steatosis induced by orotic acid.
Su GM; Sefton RM; Murray M
J Pharmacol Exp Ther; 1999 Dec; 291(3):953-9. PubMed ID: 10565810
[TBL] [Abstract][Full Text] [Related]
30. Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh.
Choi EY; Chang W; Lim S; Song BW; Cha MJ; Kim HJ; Choi E; Jang Y; Chung N; Hwang KC
Eur J Pharmacol; 2010 Feb; 627(1-3):56-62. PubMed ID: 19883640
[TBL] [Abstract][Full Text] [Related]
31. eNOS/Hsp70 interaction on rosuvastatin cytoprotective effect in neonatal obstructive nephropathy.
Manucha W; Kurbán F; Mazzei L; Benardón ME; Bocanegra V; Tosi MR; Vallés P
Eur J Pharmacol; 2011 Jan; 650(2-3):487-95. PubMed ID: 20940012
[TBL] [Abstract][Full Text] [Related]
32. Blockade of geranylgeranylation by rosuvastatin upregulates eNOS expression in human venous endothelial cells.
Landsberger M; Jantzen F; Könemann S; Felix SB
Biochem Biophys Res Commun; 2005 Nov; 336(4):1005-9. PubMed ID: 16165089
[TBL] [Abstract][Full Text] [Related]
33. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis.
Schupp N; Schmid U; Heidland A; Stopper H
Atherosclerosis; 2008 Aug; 199(2):278-87. PubMed ID: 18154958
[TBL] [Abstract][Full Text] [Related]
34. Effects of rosuvastatin on fibrinolytic system of human umbilical vein endothelial cells in vitro.
He F; Zhao J; Guo R; Liang Y
Am J Med Sci; 2014 Oct; 348(4):319-23. PubMed ID: 24694789
[TBL] [Abstract][Full Text] [Related]
35. Is rosuvastatin protective against on noise-induced oxidative stress in rat serum?
Koc ER; Ersoy A; Ilhan A; Erken HA; Sahın S
Noise Health; 2015; 17(74):11-6. PubMed ID: 25599753
[TBL] [Abstract][Full Text] [Related]
36. Rosuvastatin restored adrenergic and nitrergic function in mesenteric arteries from obese rats.
Blanco-Rivero J; de las Heras N; Martín-Fernández B; Cachofeiro V; Lahera V; Balfagón G
Br J Pharmacol; 2011 Jan; 162(1):271-85. PubMed ID: 20840472
[TBL] [Abstract][Full Text] [Related]
37. Rosuvastatin may modulate insulin signaling and inhibit atherogenesis beyond its plasma cholesterol-lowering effect in insulin-resistant mice.
Guo H; Lv H; Tang W; Chi J; Liu L; Xu F; Ji Z; Zhai X; Peng F
Cardiovasc Drugs Ther; 2012 Oct; 26(5):375-82. PubMed ID: 22918601
[TBL] [Abstract][Full Text] [Related]
38. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
Qin S; Koga T; Ganji SH; Kamanna VS; Kashyap ML
Metabolism; 2008 Jul; 57(7):973-9. PubMed ID: 18555840
[TBL] [Abstract][Full Text] [Related]
39. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
Stalker TJ; Lefer AM; Scalia R
Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
[TBL] [Abstract][Full Text] [Related]
40. Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization.
Naples M; Federico LM; Xu E; Nelken J; Adeli K
Atherosclerosis; 2008 May; 198(1):94-103. PubMed ID: 18093597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
